Skip to content

Clinical evaluation of tonifying kidney and activating blood Chinese medicine combined with UDCA in the treatment of primary biliary cirrhosis

Clinical evaluation of tonifying kidney and activating blood Chinese medicine combined with UDCA in the treatment of primary biliary cirrhosis

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026983
Enrollment
Unknown
Registered
2019-10-27
Start date
2019-01-01
Completion date
Unknown
Last updated
2019-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary biliary cirrhosis

Interventions

Experimental group:Traditional Chinese medicine granules for tonifying kidney and promoting blood circulation
Control group:Simulator of the Traditional Chinese medicine granules for tonifying kidney and promoting blood circulation

Sponsors

Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Signed informed consent; 2. Male or female aged 18 to 65 years; 3. TCM syndrome differentiation for Yin deficiency and blood stasis of liver and kidney; 4. Clinical diagnosis of western medicine conforms to the diagnostic criteria of PBC and patients belonging to stage 2 and stage 3.

Exclusion criteria

Exclusion criteria: 1. Combined with drug-induced liver injury, autoimmune hepatitis a, b, c, e, etc. 2. Patients with serious primary diseases of heart, brain, kidney, lung, endocrine, blood, metabolism and gastrointestinal tract, or mental illness; 3. Creatinine (Cr) above the upper limit of normal value; 4. Dieters who use drugs; 5. An alcoholic or drug addict; 6. Pregnant women who are lactating or preparing for pregnancy in the near future and those who use estrogen for contraception; 7. Persons who are allergic to a variety of drugs, this medicine or the components of this prescription; 8. Those who are in critical condition and have difficulty in evaluating the effectiveness and safety of new drugs; 9. Patients are reluctant to cooperate.

Design outcomes

Primary

MeasureTime frame
Clinical effective rate;Clinical symptom score;Liver function;

Countries

China

Contacts

Public ContactXing Lianjun

Pudong Branch, Longhua Hospital affiliated to Shanghai University of Chinese Medicine

xingdoctor@126.com+86 13601661366

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026